Applied Therapeutics Logo
US03828A1016
A2PHHB
APLT

Applied Therapeutics

A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 0,23 (+163,46%). A mediana é € 0,23 (+163,46%).

Comprar
  5
Manter
  5
Vender
  1

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Applied Therapeutics delisted from Nasdaq after takeover by Cycle Group

    Applied Therapeutics has completed its merger with Cycle Group Holdings and is now an indirect wholly owned subsidiary of Cycle Group. Cycle Group subsidiary AT2B acquired all outstanding shares for $0.088 per share; shareholders also received a non-tradable CVR with potential payments of up to $0.40. Applied filed to suspend trading, delist and deregister with the SEC; the board and several executives resigned, and James Harrison took over leadership. Cycle is integrating the lead drug candidate Govorestat into its portfolio; analysts sharply cut ratings and price targets for Applied stock following the transaction. » Mais em de.investing.com


  • Cycle extends takeover offer for Applied Therapeutics

    Cycle Group Holdings has extended the deadline for its takeover offer for Applied Therapeutics to 11:59 p.m. ET on January 29, 2026. Cycle is offering $0.088 per share in cash plus a non-tradable contingent value right; the price is close to the stock’s 52-week low. The board of directors of Applied Therapeutics unanimously recommends tendering the shares and warns that, if tendering is insufficient, liquidation and the immediate repayment of an $8.5 million promissory note to Cycle would likely follow. Financial data show a weak financial picture with negative EBITDA and significant financial challenges for Applied Therapeutics. » Mais em de.investing.com


  • Applied Therapeutics explores strategic alternatives and cuts 46% of workforce

    Applied Therapeutics has launched a process to evaluate strategic options such as M&A, partnerships and licensing agreements to maximize shareholder value. At the same time, the company is reducing costs by cutting 46% of its workforce; it did not disclose exact employee numbers. The stock fell sharply last year and the company reported a negative EBITDA of USD 99.61 million, but says it has more cash than debt. Applied Therapeutics is reviewing FDA Type C meeting minutes for its lead candidate govorestat and considering next steps, after also agreeing a $75 million share sale facility with Cantor Fitzgerald. » Mais em de.investing.com


  • Applied Therapeutics stock plunges after uncertainty in FDA approval process for Govorestat

    Applied Therapeutics shares fell about 55% in pre-market trading after the company said the next steps for a Govorestat approval filing, including a potential accelerated submission, have not been determined. Applied is waiting for the official FDA meeting minutes to decide how to proceed; it had previously aimed for a submission in Q3 2025. Govorestat is being developed to treat the rare neuropathy CMT‑SORD and already has multiple regulatory special designations in the US and Europe. » Mais em de.investing.com


  • FDA discussion on Govorestat sends Applied Therapeutics stock sharply higher

    Applied Therapeutics completed a meeting with the FDA about a potential regulatory filing for Govorestat to treat CMT‑SORD. The stock jumped sharply after investors learned of the discussion; the company is now waiting for the official meeting minutes before determining next steps. Govorestat has orphan drug status from the FDA and EMA and is also being developed for other rare diseases. Applied Therapeutics has also entered an agreement for an at‑the‑market equity offering of up to USD 75 million to raise capital. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Applied Therapeutics registou receitas de € 852,13 mil e um ganho líquido de -€ 16,18 mi
(EUR) setembro de 2025
YoY
Receitas 852,13 mil -
Ganho bruto 852,13 mil -
Ganho líquido -16,18 mi -
EBITDA -16,09 mi -

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 13,5 mi
Número de ações
144,3 mi
Máximo/mínimo de 52 semanas
€ 1,36 - € 0,0818
Dividendos Não
Beta
2,08
PER (PE Ratio)
-0,37
PEG (PEG Ratio)
0,00
P/VC (PB Ratio)
-26,72
P/V (PS Ratio)
14,86

Perfil da empresa

A Applied Therapeutics, Inc., uma empresa biofarmacêutica em fase clínica, desenvolve produtos inovadores para tratar doenças cardiovasculares, galactosemia e complicações diabéticas. O seu principal candidato a produto é o AT-007, que concluiu a fase 1/2 para o tratamento da galactosemia em voluntários saudáveis e adultos, e que se encontra também em estudo clínico pediátrico para o tratamento da galactosemia em crianças; para o tratamento da deficiência de desidrogenase de sorbitol; e para o tratamento da enzima fosfomanomutase CDG. A empresa desenvolve ainda o AT-001, que se encontra em ensaios clínicos de fase III para o tratamento da cardiomiopatia diabética, bem como para o tratamento da neuropatia periférica diabética. Os seus produtos em fase pré-clínica incluem o AT-003 para o tratamento da retinopatia diabética; e o AT-104, um inibidor de PI3K para o tratamento da leucemia linfoblástica aguda de células T, uma oncologia hematológica órfã. A Applied Therapeutics, Inc. foi constituída em 2016 e tem sede em Nova Iorque, Nova Iorque.

Nome
Applied Therapeutics
CEO
Les D. Funtleyder
Sede New York City, ny
EUA
Site
Setor
Materiais básicos
Indústria
Produtos químicos
Entrada em bolsa
14/05/2019
Colaboradores 35

Símbolos de ticker

Bolsa Símbolo
NASDAQ
APLT
Frankfurt
2UV.F
Düsseldorf
2UV.DU
München
2UV.MU
🍪

Parqet  utiliza cookies. Saber mais